- Home
- VTYX vs CRML Comparison
VTYX vs CRML Comparison
Compare VTYX & CRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- CRML
- Stock Information
- Founded
- VTYX 2018
- CRML N/A
- Country
- VTYX United States
- CRML United States
- Employees
- VTYX N/A
- CRML N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- CRML
- Sector
- VTYX Health Care
- CRML
- Exchange
- VTYX Nasdaq
- CRML NYSE
- Market Cap
- VTYX 154.9M
- CRML 147.9M
- IPO Year
- VTYX 2021
- CRML N/A
- Fundamental
- Price
- VTYX $2.26
- CRML $2.49
- Analyst Decision
- VTYX Buy
- CRML
- Analyst Count
- VTYX 4
- CRML 0
- Target Price
- VTYX $11.33
- CRML N/A
- AVG Volume (30 Days)
- VTYX 2.3M
- CRML 5.5M
- Earning Date
- VTYX 08-07-2025
- CRML 02-01-2025
- Dividend Yield
- VTYX N/A
- CRML N/A
- EPS Growth
- VTYX N/A
- CRML N/A
- EPS
- VTYX N/A
- CRML N/A
- Revenue
- VTYX N/A
- CRML $476,979.00
- Revenue This Year
- VTYX N/A
- CRML N/A
- Revenue Next Year
- VTYX N/A
- CRML N/A
- P/E Ratio
- VTYX N/A
- CRML N/A
- Revenue Growth
- VTYX N/A
- CRML 326.80
- 52 Week Low
- VTYX $0.78
- CRML $1.23
- 52 Week High
- VTYX $3.39
- CRML $12.00
- Technical
- Relative Strength Index (RSI)
- VTYX 56.94
- CRML 62.35
- Support Level
- VTYX $2.10
- CRML $2.10
- Resistance Level
- VTYX $2.42
- CRML $2.98
- Average True Range (ATR)
- VTYX 0.22
- CRML 0.35
- MACD
- VTYX -0.02
- CRML 0.13
- Stochastic Oscillator
- VTYX 53.99
- CRML 51.77
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.